期刊文献+

多瑞吉和奥施康定治疗癌痛的效果观察 被引量:9

Observation of therapeutic efficacy and toxicity of Durogesic and OxyContin in moderate or severe cancer pain
下载PDF
导出
摘要 目的对比观察多瑞吉(芬太尼透皮贴剂)和奥施康定(盐酸羟考酮控释片)在治疗中、重度癌症疼痛中的止痛效果和不良反应。方法将110例中、重度癌痛患者随机分为两组。多瑞吉组56例,初治患者最初剂量为25μg/h,外用,入组前使用过吗啡的患者多瑞吉剂量(μg/h)=每日吗啡剂量×0.5。奥施康定组54例,未使用过吗啡者给予10 mg,口服,q12h,入组前使用过吗啡的患者奥施康定剂量=每日吗啡剂量×0.5。根据疼痛缓解情况调整剂量,调整到患者满意的疼痛程度,即数字评分法(NRS)0~3。密切观察药物剂量、止痛效果、副作用、药物依赖性等,填写疼痛观察表。结果多瑞吉组疼痛缓解率为89.3%,奥施康定为88.9%,两组比较差异无统计学意义(P>0.05)。两组患者生活质量均明显提高,组内前后比较差异有高度统计学意义(P<0.01),组间比较差异无统计学意义(P>0.05)。多瑞吉组不良反应发生率:恶心、呕吐占10.7%,便秘占19.6%,头晕占8.9%;奥施康定组分别为18.5%、22.2%、12.9%。数值上奥施康定组高于多瑞吉,但差异无统计学意义(P>0.05)。无呼吸抑制、成瘾发生。结论多瑞吉和奥施康定均适用于中、重度癌性疼痛治疗,疗效确切,能提高疼痛患者生活质量。多瑞吉使用方便,副作用轻,略优于奥施康定。 Objective To observe the efficacy and adverse reactions of Durogesic and OxyContin in the treatment of patients with moderate or severe cancer pain.Methods 110 patients with moderate or severe cancer pain were randomly divided into 56 cases of Durogesic regimen group and 54 cases of OxyContin group.Durogesic group patients were treated with Durogesic for external use.The initial dosage of initially treated patients was 25 μg/h.The patients treated with strong opioids previously were carried out the dose conversion of Durogesic according to the conditions of administration.Durogesic doses(μg/h) = daily morphine dose × 0.5.OxyContin group patients take OxyContin per os.The initial dosage of initially treated patients was 10 mg q12h.The patients treated with strong opioids previously were carried out the dose conversion of OxyContin according to the conditions of administration.OxyContin doses = daily Morphine dose × 0.5.Doses should be adjusted until pain relief to NRS 0-3.The drug dose,efficacy,side effects,drug dependence treatment were closely observed.The standard pain observation table was filled out.Results The total alleviating rate of patients in the Durogesic group was 89.3%(50/56) and in the OxyContin group was 88.9%(48/54).Durogesic and OxyContin also improved the quality of life of the patients with cancer pain.No significant differences were found between two groups(P 0.05).The quality of life of the patients in the two groups was improved,there were significant differences of the two groups before and after treatment(P 0.01),while there were no significant differences between the two groups(P 0.05).The chief adverse reactions were nausea,constipation,dizziness and lethargy.Each reaction of Durogesic group were 10.7%,19.6%,8.9%;OxyContin group were 18.5%,22.2%,12.9%.The difference between the two groups was not statistically significant(P 0.05).No respiratory inhibition and addiction occurred.Conclusion Durogesic and OxyContin are proved to be good,slight side effect.And Durogesic is convenient in the control of cancer pain.
出处 《中国医药导报》 CAS 2012年第35期107-109,共3页 China Medical Herald
基金 江苏省卫生厅科研项目(项目编号:H200913) 江苏省普通高校研究生科研创新计划项目(项目编号:CXLX11_0725)
关键词 癌症疼痛 多瑞吉 奥施康定 疗效 副作用 Cancer pain Durogesic OxyContin Therapeutic effect Side effects
  • 相关文献

参考文献9

  • 1Lu L,Zeng J,Chen Y. Quality of reporting in randomized controlled tri- als conducted in China on the treatment of cancer pain [J]. Expert Rev Anticaneer Ther,2011,11 (6) :871-877.
  • 2Hjermstad MJ,Fayers PM,Haugen DF,et al. Studies comparing numeri- cal rating scales ,verbal rating scales, and visual analogue scales for as- sessment of pain intensity in adults:a systematic literature review [J]. J Pain Symptom Manage ,2011,41 (6) : 1073-1093.
  • 3张冠中,谢晓冬,刘大为.盐酸羟考酮控释片治疗晚期癌症疼痛的临床应用[J].中国肿瘤临床,2007,34(2):72-74. 被引量:25
  • 4Terret C,Albrand G,Moncenix G,et al. Karnofsky performance scale (KPS)or physical performance test(PPT)? That is the question [J]. Crit Rev Oncol Hemato1,2011,77(2) : 142-147.
  • 5Elkins G,Johnson A,Fisher W. Cognitive hypnotherapy for pain man- agement [J]. Am J Clin lqypn,2012,54(4):294-310.
  • 6Plante GE, Vanltallie TB. Opioids for cancer pain : the challenge of opti- mizing treatment [J]. Metabolism,2010,59 (Suppl 1):47-52.
  • 7Elsner F,Zeppetella G,Porta-Sales J,et al. Newer generation fentanyl transmueosal products for breakthrough pain in opioid-tolerant cancer patients [J]. Clin Drug Investig ,2011,31 (9) :605-618.
  • 8Bilen A,Ali A,Alkan I,et al. Comparison of transdermal fentanyl for the management of cancer pain in adults and elders [J]. Agri,2012,24(3): 111-116.
  • 9Ravera E,Di SS,Bosco R,et al. Controlled-release oxyeodone tablets after transdermal-based opioid therapy in patients with caneer and non-cancer pain [J]. Aging Clin Exp Res,2011,23(5-6) :328-332.

二级参考文献9

  • 1刘华,王蔚,郑垂志,邢雪花.癌症三阶梯止痛563例分析[J].中国肿瘤临床,2004,31(23):1346-1348. 被引量:79
  • 2李小梅,刘端祺,李红英,王艳梅.恶性肿瘤患者临终前的阿片类药物止痛回顾[J].中国肿瘤临床,2005,32(23):1358-1360. 被引量:36
  • 3孙燕.内科肿瘤学[M].北京:人民卫生出版社,1999.88.
  • 4Kapil R,Nolting A,Roy P,et al.Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen:two randomized,open-label,crossover studies in healthy adult volunteers[J].Clin Ther,2004,26(12):2015~2025
  • 5Arcuri E,Ginobbi P,Tirelli W,et al.Preliminary in vivo experimental evidence on intratumoral morphine uptake.Possible clinical implications in cancer pain and opioid pesponsiveness[J].J Pain Symptom Manage,2002,24(1):1~3
  • 6Clohisy DR,Mantyh PW.Bone cancer pain[J].Cancer,2003,79(3 Suppl):866~873
  • 7Smith MT,Ross FB,Nielsen CK,et al.Oxycodone has a distinctly different pharmacology from morphine[J].Eur J Pain,2001,5(suppl.A):135~136
  • 8Hermos JA,Young MM,Gagnon DR,et al.Characterizations of long-term oxycodone/acetaminophen prescriptions in veteran patients[J].Arch Intern Med,2004,164(22):2361~2366
  • 9于世英,邱红,马振山,陈嘉,张英,陈立正,王东林,马智勇.盐酸吗啡缓释片治疗癌症疼痛的临床疗效分析[J].中华医学杂志,2004,84(6):450-455. 被引量:33

共引文献24

同被引文献60

  • 1郭环宇,王玲玲,景年财.以奥施康定为初始滴定治疗中、重度癌痛的疗效[J].中国老年学杂志,2014,34(12):3285-3286. 被引量:33
  • 2郭红,孙艳,陈海滨.芬太尼透皮贴剂在肝癌介入治疗后疼痛的疗效观察[J].中国医刊,2007,42(3):38-39. 被引量:1
  • 3陈新谦,金有豫,汤光.新编药物学[M].17版.北京:人民卫生出版社,2011:3465.
  • 4陈奕贵,杨建伟,李惠,等.奥施康定治疗200例中重度癌痛临床体会[J].药品评价,2012,9(3):33.
  • 5Caraceni A ,Martini C ,Zecca E ,et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey[J]. Palliat Med 2004,18 : 177-183.
  • 6Delaney A,Fleetwood-Walker SM, C olvin LA,et al. Translational medic ine: cancer pain mechanisms and management[J]. Br J Anaesth ,2008, 101 : 87-94.
  • 7Goudas LC, Bloch R,Gialeli-Goudas M,et al. The epidemiology of cancer pain[J]. Cancer Invest, 2005,23 (2) : 182-190.
  • 8刘肖平.阿片类药在癌痛治疗时能否产生依赖[J].实用疼痛学杂志,2007,3(5):325-327. 被引量:6
  • 9寇军燕,丁纪元,李俊,等.奥施康定与多瑞吉治疗中重度癌痛疗效与费用分析[C].//第八届全国癌症康复与姑息医学大会论文集,2012:52-55.
  • 10NCCN.org.Adult Cancer Pain-NCCN Clinical Practice Guidelines (Version I.2014)[OB/OL].http://www.nccn.org/ pro fessionals/physician_gls/f_guidelines.asp#pain.

引证文献9

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部